C. Jillian Tsai: A very thoughtful opinion piece on caveats of using TTMV-HPV DNA in oropharyngeal carcinoma
C. Jillian Tsai, Radiation Oncologist at Princess Margaret Cancer Centre, Toronto, Canada shared a post on X:
“A very thoughtful opinion piece by Nancy Lee, Memorial Sloan Kettering Radiation Oncology, Luc Morris, Max Diehn outlining the caveats of using TTMV-HPV DNA as a routine biomarker for surveillance and treatment decision-making. Given the lack of robust sensitivity, such application should be carried out in clinical trials.
Assessing the Evidence for Circulating Tumor HPV DNA in Patients With Oropharyngeal Cancer.”
Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology at National Cancer Centre Singapore shared C. Jillian Tsai post on X, adding:
“While they may share several commonalities thus arguing for common treatment principles, this is when jumping the gun leads to a koolaid moment.
We need independent trials of using TTMV-HPV DNA for prognostication and surveillance in HPV+OPSCC.”
Source: C. Jillian Tsai/X and Melvin LK Chua/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023